CCPLs and the acetylcholinesterase inhibitors were the treatments more largely studied in clinical trials for the AD consistent with the hypothesis that a replacement/enhancement of the cholinergic function may be useful in the treatment of AD patients. The gene discussed is ACHE; the disease is Alzheimer disease.